BioFund Management Oy has sold all shares of Ark Therapeutics Group Plc, a biopharmaceutical company based in Finland and the UK. Bio Fund Ventures II LP invested in Ark in 2000 and Ark was listed on the London Stock Exchange main list in March 2004.
Company has raised €20m so far over two funding rounds
HV Holtzbrinck and Lakestar also participate in the round for the dental technology startup
IK VIII held a final close in November 2016 with €1.85bn and was 87% deployed as of December 2019
With the GP's support, Bomi intends to pursue an intensive buy-and-build strategy